Sanofi's Praluent, GSK's malaria vax up for CHMP backing this week; Novartis contends Lucentis more cost-effective than Eylea;

@FiercePharma: India's Torrent completes deal to buy family-run Zyg Pharma, gets FDA plant. More from FiercePharmaAsia | Follow @FiercePharma

@CarlyHFierce: ICYMI: Bayer homes in on €10B plastics IPO with plans for summer roadshow. Report | Follow @CarlyHFierce

> Sanofi ($SNY) and Regeneron's ($REGN) cholesterol drug Praluent and GlaxoSmithKline's ($GSK) malaria vaccine could win backing from E.U. regulators as soon as this week. Report

> Novartis ($NVS) says its eye drug Lucentis is more cost-effective than Bayer's Eylea for treating diabetic macular edema, in an analysis published in ClinicoEconomics and Outcomes Research. Report

> Baxter ($BAX) pulled two lots of its saline solution after a customer complaints about insect particles in the IV bags. Report

> Sun Pharma said its merger with Ranbaxy Laboratories would take a toll on its revenue and profits, partly because of the costs of integrating the two companies and fixing problems at Ranbaxy facilities. Report

> European officials approved CSL's buyout of Novartis' flu vaccines business. Report

Medical Device News

@FierceMedDev: Alere revs up engine with new deals and win for quick strep test. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Indian stentmakers gaining global foothold--is U.S. market next? More | Follow @VarunSaxena2

@EmilyWFierce: Kim Kardashian speaks out for Duchesnay's morning sickness drug, Diclegis. FiercePharmaMarketing press release | Follow @EmilyWFierce

> Boston Scientific faces reimbursement hurdles for lung-searing asthma treatment. Story

> UCLA adopts startup cleaning system to help stop spread of superbugs via duodenoscopes. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Tekmira changes its name and shuffles away from Ebola. News | Follow @FierceBiotech

@JohnCFierce: ICYMI: Adaptimmune touts a promising snapshot of TCRs for myeloma. More | Follow @JohnCFierce

@DamianFierce: You can watch The Atlantic's AAIC2015-adjacent chat thing, ft. $LLY, here. | Follow @DamianFierce

> Big Pharma pushes new migraine drugs into Phase III with blockbuster hopes. Item

> 'Cures' bill, designed to speed drug approvals, could be too much of a good thing, dissenters say. More

> Athyrium debuts a $1.2B fund to bet on biopharmas. Article

Drug Delivery News

> Two oral therapeutics specialists bag a combined $140M via IPO, VC funding. Item

> Glucose delivery pathway that feeds tumors could be exploited to knock them down. More

> Minimally invasive brain probe uses light flashes to target drugs. Story

> Purdue team developing smart capsule for diseases of the large intestine. Report

> Novo to sell shield for concealing the needle of its injection pens. Article

Pharma Manufacturing News

> Biogen gets all of North Carolina site from Eisai as part of manufacturing build-out. Story

> Amgen's Colorado plant hits the market for $85M. Item

> Valeant gets manufacturing in Middle East with deal for Amoun. More

> Baxter IDs particulate in recalled saline as insects. Article

> AMRI picks up Spanish drugmaker in $174M deal. News

Pharma Asia News

> AdvaMed welcomes legislation to separate India's device and drug oversight. Item

> ASLAN and Singapore's NCCS plan studies on Asia-prevalent cancers. More

> India's Sun Pharma sees multiyear earnings hit as it fixes plants, integrates Ranbaxy. Report

> Medidata's de Vries on disruption in Asia drug research with Japan a focus. Story

> Singapore's biopharma industry: Where the jobs are. Article

And Finally... People at high risk of contracting HIV took their preventive meds--pre-exposure prophylaxis, or PrEP--mostly as directed in a new study; despite FDA approval to stave off HIV infection, Gilead Sciences' ($GILD) Truvada hasn't been widely adopted for that use. Release

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.